









PublishedPoor glycemic control as a risk factor
for pseudophakic cystoid macular edemain patients with diabetes
Petteri Ylinen, MD, Ilkka Laine, BSc, Juha-Matti Lindholm, MD, Raimo Tuuminen, MD, PhD, FEBOPurpose: To specify the risk factors for pseudophakic cystoid
macular edema (CME) in patients with diabetes.
Setting: Kymenlaakso Central Hospital, Unit of Ophthalmology,
Kotka, Finland.
Design: Prospective case series.
Methods: Patients with type 1 or type 2 diabetes having routine
cataract surgery were evaluated. Spectral-domain optical coherence
tomography imaging was performed before surgery and 1 month
postoperatively.
Results: The study comprised 93 patients (95 eyes). The cen-
tral retinal thickness increase was 9.7 mm G 1.7 (SEM) in dia-
betic patients with no retinopathy, 22.7 G 8.6 mm in those who
had nonproliferative retinopathy, and 73.8 G 37.4 mm in those
who had proliferative retinopathy (P < .001). The central retinal
thickness increase was greater in the eyes of diabetic patients
with insulin dependence than in eyes of patients usingJune 26, 2017 | Accepted: July 26, 2017
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by Elsevier Inc.noninsulin medication (21.9 G 5.9 mm versus 8.3 G 1.8 mm,
P Z .017). Serum hemoglobin A1c concentration and inversely,
patient age, were associated with central retinal thickness in-
crease, even after adjustment for confounding factors
(r Z 0.607, P < .001 and r Z 0.417, P Z .001, respectively).
The central retinal thickness change was smaller in the eyes of
patients who had a nonsteroidal antiinflammatory drug (NSAID)
as their postoperative antiinflammatory medication than in eyes
of patients who were not prescribed NSAID medication when
retinopathy was analyzed as a covariant (8.2 G 3.6 mm versus
13.6 G 2.9 mm, P Z .016).
Conclusions: Young patient age and poor glycemic control were
risk factors for postoperative central retinal thickness increase. This
study showed it is necessary to identify, effectively treat, and follow-
up with patients with diabetes who are at a greater risk for
pseudophakic CME.
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Supplemental material available at www.jcrsjournal.org.Cataract surgery is the most common surgicalprocedure worldwide and with modern phacoemul-sification techniques, it is now safer than ever.
However, the procedure is not risk-free and with the high
number of operations, complications are occasionally
seen. Pseudophakic cystoid macular edema (CME)
(Irvine-Gass syndrome) is the most common postoperative
complication of cataract surgery with an incidence rate of
approximately 1.0% in patients with no known risk factors.1,2
Diabetes itself, and its coexistence with diabetic macular
edema and diabetic retinopathy (DR), have been linked to
impaired visual outcomes after uneventful cataract surgery.3,4
Despite improved systemic and ocular management of thedisease, patients with diabetes have been identified to be at
risk for pseudophakic CME, in particular those who have
diabetic macular edema and/or DR, with the level of DR
increasing the risk for pseudophakic CME.1,2,5,6 To prevent
pseudophakic CME, more aggressive antiinflammatory
medications, nonsteroidal antiinflammatory drug (NSAID)
eyedrops in particular, have been used before and after
cataract surgery.7,8 At present, there is no consensus on
whether all patients with diabetes should receive more
aggressive postoperative antiinflammatory medication;
therefore, a wide variety of corticosteroid and NSAID
treatments areusedas singular drug therapies or in combination
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1377CATARACT SURGERY IN PATIENTS WITH DIABETESAs the proportion of patients with type 1 or type 2 diabetes
continues to increase,9,10 the occurrence of pseudophakic
CME can be expected to rise. The use of optical coherence
tomography (OCT) has made the diagnosis of pseudophakic
CME more accurate and convenient, reducing the need for
fluorescein angiography (mainly used for ruling out
differential diagnosis) to a minimum.11 Previous studies
with OCT5,12,13 have shown that central retinal thickness
increases postoperatively more in patients with diabetes,
insulin dependence, and retinopathy, impairing visual
acuity gain.
This study aimed to identify the patients with diabetes
who are at the highest risk for pseudophakic CME. Specifically,
these data might facilitate a surgeon’s decision about whether a
patient requires more extensive antiinflammatory medication




Diabetic patients were admitted as per the national guidelines for
the management of cataract in the Department of Ophthalmology,
Kymenlaakso Central Hospital, Kotka, Finland. The patients were
examined by an ophthalmologist on the day of surgery and at the
1-month postoperative visit. The mean central retinal thickness
was recorded by spectral-domain OCT on both visits by an
experienced ophthalmic nurse. The study was approved by the
research director and chief medical officer of the Kymenlaakso
Central Hospital. Oral consent was obtained from each participant
before enrollment in the study, and all study participants were
examined postoperatively at Kymenlaakso Central Hospital.
Confidentiality of the patient records was maintained when the
clinical data were entered in a computer-based standardized
database for analysis.
Patients
Patients with type 1 or type 2 diabetes who were scheduled for
cataract surgery were enrolled between September 2015 and
December 2015. Exclusion criteria were patient withdrawal from
the 1-month follow-up visit or omission of postoperative
antiinflammatory medication and inability to obtain sufficient
data from OCT imaging for the central retinal thickness
comparisons.
Time from diagnosis of diabetes; topical and systemicmedication;
glycemic control (hemoglobin A1c [HbA1c]); history of laser photo-
coagulation, intravitreal treatment, and surgery; posterior segment
status (eg, the degree of DR, existence of diabetic maculopathy,
existence of age-related macular degeneration [AMD]); and other
ocular comorbidities were recorded. The latest HbA1c level was
used and patients without an HbA1c measurement within 1 year
were not included in the study. Intraoperatively, axial length (AL),
duration of the surgery, cumulative dissipated energy, and use of
an intraocular surgical aidda capsular tension ring (CTR) (Stabileyes,
Abbott Medical Optics, Inc.) or a 6.25 mm pupil-expansion device
(Malyugin Ring, Microsurgical Technology)dwere recorded.
Postoperative Antiinflammatory Medication
The postoperative antiinflammatory medication was corticosteroid
(dexamethasone sodium phosphate 1.32 mg/mL, Oftan Dexa) 3
times a day for 3 weeks. The decision to use an NSAID (nepafenac
10 mg/mL, Nevanac) 3 times a day for 3 weeks in combination with
a corticosteroid (15 eyes of 15 patients) was made by the operating
physician. One of the patients did not tolerate dexamethasone
sodium phosphate as a postoperative antiinflammatory medication
and was treated only with nepafenac.Surgical Technique
A standardized phacoemulsification technique was used in all
cataract surgeries. A 2.75 mm clear cornea incision was followed
by capsulorhexis, phacoemulsification (divide-and-conquer),
and intraocular lens (IOL) placement in the capsular bag. An
Ozil phacoemulsification handpiece and a 0.9 mm 30-degree
beveled Kelman tip were used in the phacoemulsification system
(Infiniti, Alcon Surgical, Inc.). In all cases, anesthesia was topical.
Hyaluronic acid 1.6%–chondroitin sulfate 4.0% (Discovisc) was
used as the ophthalmic viscosurgical device. Aspheric hydrophobic
single-piece monofocal IOLs were used (Tecnis, PCB00, Abbott
Medical Optics, Inc. or Acrysof IQ, SN60WF, Alcon Surgical,
Inc.). Antimicrobial medication included intraoperative intra-
cameral cefuroxime (Aprokam) and postoperative levofloxacin
5 mg/mL (Oftaquix) eyedrops 3 times a day for 1 week.
Clinical Evaluation
The corrected distance visual acuity (CDVA) was evaluated preop-
eratively by the referring ophthalmologist and postoperatively
with an autorefractometer (AR-1s, Nidek Co. Ltd.) at standardized
light conditions. Intraocular pressure was measured with rebound
tonometry (iCare tonometer, Revenio Group Oyj).
The biometry was evaluated on the day of surgery using the
IOLMaster 500 (Carl Zeiss Meditec AG), and the Haigis formula14
was used for IOL power calculations.
Diabetic retinopathy was evaluated by clinical assessment and
graded on a 5-stage severity classification as none, background,
moderate nonproliferative, severe nonproliferative, or prolifera-
tive DR according to international clinical classification systems
for DR.15,16 For statistical purposes, DR was graded as
0 Z none, 1 Z nonproliferative (background, moderate, and se-
vere nonproliferative), and 2 Z proliferative DR.
Follow-up 30-frame scans were performed with Autorescan
software and preoperative OCT analyses were compared with
those obtained 1 month after surgery (Heidelberg Eye Explorer,
version 1.9.10.0 and HRA Spectralis Viewing Module, version
6.0.9.0, Heidelberg Engineering GmbH).
Pseudophakic CME was diagnosed by a clinician at the control
visit. The diagnosis of pseudophakic CME was based on clinical
signs and typical OCT findings.12
Statistical Analyses
Data are given as means G SEM, except for the absolute
numbers and proportions for the nominal scale. Statistical
analysis was performed using IBM SPSS Statistics software
(version 24, IBM Corp.). For 2-group comparisons, qualitative
data were analyzed with the 2-factor chi-square test (or with
the Fisher exact test when values in any of the cells of a
contingency table were below 5) and ordinal measurement scale,
and continuous variables with the nonparametric Mann-Whitney
U test. Multiple groups were compared with the control by using
the nonparametric Kruskal-Wallis with the Dunn test. The Dunn
post hoc test was applied only if the Kruskal-Wallis test showed
an overall statistically significant difference. A linear regression
model was used to estimate the relationships between variables,
and multiple regression was used to include specific variables in
the model, such as type of diabetes and existence of posterior
segment comorbidities (diabetic maculopathy, level of DR, dry
AMD). A P value of 0.05 or less was considered statistically
significant.
RESULTS
The study recruited 103 patients (105 eyes) with type 1 or
type 2 diabetes. Of these, 2 patients were excluded because
they were unable to meet the 1-month follow-up, 1 patient
was excluded because of omission of postoperative
antiinflammatory medication, and 7 patients were excludedVolume 43 Issue 11 November 2017

































CDVAZ corrected-distance visual acuity; CRTZ central retinal thickness;
DM Z diabetes mellitus; HbA1c Z hemoglobin A1c; HM Z hand move-
ment; n Z number of patients; NPDR Z nonproliferative diabetic retinop-
athy; PDR Z proliferative diabetic retinopathy
1378 CATARACT SURGERY IN PATIENTS WITH DIABETESbecause of inability to obtain sufficient data from OCT
imaging for the central retinal thickness comparisons.
Thus, the analysis comprised 93 patients (95 eyes).
Seven patients (7 eyes) had type 1 diabetes, and 86 patients
(88 eyes) had type 2 diabetes. The mean duration of diabetes
was 14.8 years and the mean level of HbA1c was 7.0%
(53 mmol/mol). Overall, 35 patients were insulin dependent.
Eleven study eyes had DR of which 4 had background, 3 had
preproliferative, and 4 had the proliferative form. Diabetic
maculopathy was present in 9 eyes and clinically relevantVolume 43 Issue 11 November 2017diabetic macular edema in 5 eyes. Six eyes had partial or
panretinal laser photocoagulation treatment based on the
form of retinopathy, and 4 eyes were treated with macular
grid laser photocoagulation. Dry AMD was diagnosed in
17 eyes and epiretinal membrane or vitreomacular traction
was diagnosed in 11 eyes.
Table 1 shows the patients’ baseline characteristics.
Preoperatively, the mean CDVA was 0.32 G 0.01 decimals
in the Snellen chart and the mean central retinal thickness
was 287.9 G 5.8 mm. The mean operation time was
19.6 G 0.9 minutes and the phaco energy (cumulated
dissipated energy) was 16.4 G 2.0 seconds. A pupil-expansion
device was used in 3 surgeries and CTR in 2 surgeries. No eye
had iris prolapse or vitreous loss.
Central Retinal Thickness
Diabetic Patients with Insulin Dependence The mean central
retinal thickness increase was 21.9 G 5.9 mm in the eyes of
diabetic patients with insulin dependence and 8.3 G 1.8 mm
in those with noninsulin medication (P Z .017) (Figure 1,
A). The mean central retinal thickness increase was
34.9 G 13.6 mm in type 1 diabetes and 18.6 G 6.5 mm in
type 2 diabetic patients with insulin dependence (Figure S1,
A and B, available at: www/jcrsjournal.org). The time from
the diagnosis of diabetes was not associated with the central
retinal thickness change (r Z 0.032, PZ .765) (Figure 1, B).
Hemoglobin A1c Serum Concentrations Serum HbA1c concen-
tration, reflecting poor glycemic control, was associated with
central retinal thickness increase (r Z 0.523, P ! .001)
(Figure 1, C). The HbA1c concentration was higher in patients
who had type 1 diabetes than in patients with type 2 diabetes
(P! .001) (Table S1, available at: www/jcrsjournal.org), and
the association between serum HbA1c and central retinal
thickness increase remained significant in regression analysis
of patients with type 2 diabetes only (r Z 0.518, P ! .001)
(Figure 1, C). Moreover, in the multivariate linear regression
model with diabetic posterior segment manifestations (macu-
lopathy and level of retinopathy) and type of diabetes as
confounding factors, the association between serum HbA1c
and central retinal thickness increase remained significant
(rZ 0.607) (P! .001).
Proliferative Diabetic Retinopathy In patients having diabetic
maculopathy, the mean central retinal thickness increase
was 37.3 G 20.6 mm compared with those with no macu-
lopathy 10.7 G 1.6 mm (P Z .647) (Figure 2, A). The meanFigure 1. The effect of (A) insulin
dependence on the central retinal
thickness change 1 month after
uncomplicated cataract surgery.
Correlation between (B) duration
of diabetes in years since diagnosis
and (C) serum level of HbA1c on the
central retinal thickness change
(*Z P% .05; CRTZ central retinal
thickness; DMZ diabetesmellitus;
HbA1c Z hemoglobin A1c).
Figure 2. The effect of diabetic (A)
maculopathy and (B) retinopathy on
the central retinal thickness change
(*** Z P ! .001; CRT Z central
retinal thickness; NPDRZ nonproli-
ferativediabetic retinopathy; PDRZ
proliferative diabetic retinopathy).
Figure 3. The effect of (A) use of postoperative NSAID eyedrops
on the central retinal thickness change and (B) the level of central
retinal thickness change on postoperative CDVA (colored bars)
and CDVA gain (white bars) 1 month after uncomplicated cataract
surgery (* Z P % .05; CDVA Z corrected-distance visual acuity;
CRT Z central retinal thickness).
1379CATARACT SURGERY IN PATIENTS WITH DIABETEScentral retinal thickness change was 9.7 G 1.7 mm in
patients with no DR, 22.7 G 8.6 mm in those with the
nonproliferative DR form, and 73.8 G 37.4 mm in those
with proliferative DR (P ! .001) (Figure 2, B).
Use of Postoperative Antiinflammatory Medication
Fourteen eyes were treated with a combination of corticosteroid
(dexamethasone sodium phosphate 1.32 mg/mL) and NSAID
(nepafenac 10 mg/mL) eyedrops postoperatively. In addition,
1 eye was treated with only nepafenac 10 mg/mL eyedrops
postoperatively. The mean age of the patients was 70.5 years
and the mean HbA1c was 7.3% in patients receiving NSAID
drops. The central retinal thickness change in those not
receiving NSAID treatment was 13.6 G 2.9 mm and
8.2 G 3.6 mm in those receiving NSAID (P Z .227)
(Figure 3, A). Two of the 15 eyes were of patients with
type 1 diabetes. Maculopathy coexisted in 3 eyes, and DR
in 4 eyes. Baseline variables did not differ from the group
with no NSAIDs, except the level of DR (P Z .020).
When the level of DR was analyzed as a covariant (analysis
of covariance), the central retinal thickness change was less
in the eyes in the NSAID group than in the eyes with no
NSAID treatment (P Z .016).
Effect of Central Retinal Thickness Change
Visual Outcomes 1Month After SurgeryAt 1 month, the mean
decimal CDVA was 0.86 G 0.03 (mean CDVA gain
0.54 G 0.03) and the mean central retinal thickness was
301.1 G 6.7 mm (mean CRT increase 13.2 G 2.5 mm). In
eyes with the mean central retinal thickness at 1 month
that was more than 30% greater than preoperatively, the
postoperative CDVA decreased from 0.89 G 0.03 to
0.29 G 0.04 (P Z .049) and the CDVA gain was
(0.05 G 0.05 versus 0.57 G 0.04) (P Z .048) compared
with eyes with a central retinal thickness increase of less
than 20% (Figure 3, B). Based on the clinical evaluation
and OCT analysis, pseudophakic CME was refractory and
longstanding in 3 (3.2%) of the 95 eyes, and these were
treated with intravitreal injections with a sustained delivery
of 0.7 mg dexamethasone. All 3 were insulin dependent
(PZ .047) and did not receive NSAID treatment primarily
after the surgery (the difference was not statistically
significant). In non-pseudophakic CME eyes, the mean
central retinal thickness increase was 10.0G 2.9 mm (range22 to 69 mm) and in eyes with refractory pseudophakic
CME, the mean central retinal thickness increase was
113.7 G 28.9 mm (range 79 to 171 mm).
Patient Age and Diabetic Patients with Dry Age-Related
Macular Degeneration The age of the diabetic patients at
surgery was inversely associated with central retinal thick-
ness change (r Z 0.392, P ! .001) (Figure 4, A). Patients
with type 1 diabetes were younger than patients with type
2 diabetes (P ! .001) (Table S1, available at: www
/jcrsjournal.org). The inverse association between patient
age and central retinal thickness change remainedVolume 43 Issue 11 November 2017
Figure 4. A: Correlation between
patient age and the central retinal
thickness change at 1 month. B:
The effect of dryAMDon the central
retinal thickness change
(*** Z P ! .001; CRT Z central
retinal thickness; dAMD Z dry
age-related macular degeneration;
DMZ diabetes mellitus).
1380 CATARACT SURGERY IN PATIENTS WITH DIABETESsignificant in regression analysis only in type 2 diabetic
patients (r Z 0.406, P ! .001) (Figure 4, A).
Eyes with dry AMD were associated with less central
retinal thickness increase than eyes with no dry AMD
(1.9 G 1.9 mm and 16.1 G 3.0 mm) (P Z .001) (Figure 4,
B). However, the inverse association between age and central
retinal thickness change remained significant when
analyzing the eyes with no dry AMD only (r Z 0.367,
P Z .001). In the multivariate linear regression model with
the type of diabetes and presence of dry AMD as confounding
factors, inverse correlation between patient age and central
retinal thickness change remained significant (r Z 0.417,
P Z .001).Table 2. Correlation between surgical parameters and
the mean central retinal thickness change.*
Parameter Range r Value P Value
Axial length (mm) 21.1, 26.5 0.019 .862
Phaco energy (CDE) 4.1, 127.0 0.089 .485
Surgical procedure time (min) 6, 56 0.105 .334
CDE Z cumulative dissipated energy
*Linear regression modelEffect of Topical Nonsteroidal Antiinflammatory Drugs on
Central Retinal Thickness
In patients having non-insulin medication, the mean central
retinal thickness increase was 9.2G 1.9 mmwithout NSAIDs
and 1.5 G 3.1 mm with topical NSAIDs (P Z .029). In
patients with insulin dependence, the mean central retinal
thickness increase was 21.7 G 7.3 mm with no NSAIDs
and 15.9 G 5.8 mm with topical NSAIDs (P Z 0.040
compared with those using non-insulin medication)
(Figure S2, A, available at: www/jcrsjournal.org).
In eyes with no maculopathy, the mean central retinal
thickness increase was 10.9 G 1.8 mm with no NSAIDs and
9.7G 4.3 mmwith topical NSAIDs. In eyes withmaculopathy,
themeancentral retinal thickness increasewas 52.4G 35.1mm
with no NSAIDs and 2.3 G 3.8 mm with topical NSAIDs
(Figure S2, B, available at: www/jcrsjournal.org).
In eyes with no retinopathy, the mean central retinal
thickness increase was 10.5 G 1.9 mm with no NSAIDs
and 4.5 G 3.0 mm with topical NSAIDs. In eyes with
retinopathy, the central retinal thickness increase was
50.8 G 27.4 mm with no NSAIDs (P Z .045 compared
with those with no retinopathy) and 20.5 G 9.2 mm with
topical NSAIDs (Figure S2, C, available at: www
/jcrsjournal.org).
WhenNSAIDs were included as a covariant in themultivariate
linear regression model with maculopathy, level of retinopathy,
and type of diabetes as confounding factors, the association
between serumHbA1c and central retinal thickness increaseVolume 43 Issue 11 November 2017remained significant (rZ 0.639, P! .001). In addition, the
inverse relationship between patient age and central retinal
thickness remained significant when NSAIDs were
included as a covariant in the multivariate linear regression
model with dry AMD and type of diabetes as confounding
factors (r Z 0.422, P ! .001).Central Retinal Thickness Change Correlations
In eyes with an epiretinal membrane and eyes with no
epiretinal membrane and/or vitreomacular traction, the
central retinal thickness change was comparable (P Z .525,
Figure S3, available at: www/jcrsjournal.org). Neither AL
(rZ 0.019, PZ .862), phaco energy (rZ 0.089, PZ .485),
operation time (rZ 0.105,PZ .334) (Table 2), use of a pupil-
expansion device or a CTR (P Z .510), nor the educational
level of the operating physician (experienced resident versus
specialist in ophthalmology, PZ .244) (Figure S3, available
at: www/jcrsjournal.org) had an effect on the central retinal
thickness change.DISCUSSION
Pseudophakic CME remains a common cause of reduced
visual acuity gain after cataract surgery, especially in
patients with diabetes. This study identifies unreported
clinical characteristics that predispose diabetic patients to
a high risk for developing pseudophakic CME. Supporting
previous data, the level of DR was identified as a risk factor
for central retinal thickness increase. Moreover, central
retinal thickness increase was greater in patients with type
1 diabetes than in patients with type 2 diabetes, and the
central retinal thickness increase was greater in type 2
1381CATARACT SURGERY IN PATIENTS WITH DIABETESdiabetic patients who were insulin dependent than in type 2
diabetic patients who were not using insulin medication.
Glycemic oscillations postprandial (after mealtime) and
during fasting might activate oxidative stress, systemic
proinflammatory, and proapoptotic signaling pathways and
promote microvascular endothelial dysfunction and pericyte
dropout.17,18 Patients with type 1 diabetes have a higher gly-
cemic variability than patients with type 2 diabetes, regardless
of overall glycemic control.19 Given that glucose fluctuation
might differ between insulin-dependent and non-dependent
diabetic patients, and glycemic variability might promote
inflammation and vascular complications, patients with
type 1 or type 2 diabetes with insulin dependence seem to
be at greater risk for pseudophakic CME.
With univariate and multivariate regression analyses, we
found a correlation between serum levels of HbA1c and cen-
tral retinal thickness increase. This is in accordance with the
recently published data.20 The HbA1c, a simple quantitative
measure, might be used as 1 of the tools to estimate an in-
dividual’s risk for developing pseudophakic CME. The
mechanisms behind the correlation between HbA1c and
central retinal thickness are likely multifactorial and might
include secretion of inflammatory and vasoactive factors,
such as angiopoietin-2 and vascular endothelial growth fac-
tor, microvascular dysfunction, and blood–retinal barrier
breakdown.21–23 Poor glycemic control not only encourages
more aggressive antiinflammatory medication in cataract
surgery, but also better management of the disease
preoperatively.
In concurrence with the literature, dry AMD was associ-
ated with reduced macular changes after cataract surgery.2
However, the presence of dry AMD did not explain the in-
verse association between patient age and central retinal
thickness increase. Use of vasoactive medications in older
patients with diabetes might play a protective role; there-
fore, further studies evaluating the relationship between
systemic medication and posterior segment changes after
ocular surgery might prove fruitful.24–26
Our present study has some limitations. First, although
the study has a prospective design, it was not tightly
controlled. A non-diabetic control group was not included
in the study design that focused on recruiting a high num-
ber of diabetic patients. Although the study population
included only 7 eyes from type 1 diabetic patients, 3 of
the 4 proliferative DR eyes were from patients with type 1
diabetes. Multivariate analyses were performed to minimize
effect of confounding factors. Second, the postoperative use
of NSAID eyedrops in combination with corticosteroids
was left to the operating surgeon’s clinical discretion, and
seemed to be based more on the operating surgeon’s prefer-
ence than on the known risk factors in the patient popula-
tion. According to covariance analysis, postoperative use of
topical NSAIDs reduced central retinal thickness increase.
This parallels the finding that the use of an NSAID and
corticosteroid combination reduced the incidence of
pseudophakic CME after uneventful cataract surgery in a
retrospective chart review of unselected patients and in a
double-masked randomized clinical trial of patients withnonproliferative diabetic retinopathy in comparison to corti-
costeroidmonotherapy.27,28 Third, late phase follow-ups 3 to
12 months after surgery would have been warranted to
better evaluate the kinetics of central retinal thickness and
pseudophakic CME. These were, however, not included in
the study protocol monitoring the clinical practice because
clinical practices in government-based units are recom-
mended to adhere to the Current Care Guidelines of
Cataract Surgery of the FinnishMedical Society, Duodecim,
which state that a 1-month follow-up is sufficient after
uncomplicated cataract surgery.
This study encourages strict preoperative diabetes man-
agement and in select cases, intensive management for
pseudophakic CME prophylaxis. The use of more extensive
antiinflammatory medication postoperatively and perhaps
preoperatively, in particular NSAID eyedrops as a
monotherapy or in combination with conventionally used
corticosteroid eyedrops, could be justified to diminish the
risk for developing pseudophakic CME.1,8,27–29 Intraopera-
tive bevacizumab injection might also be considered as an
adjunct treatment, and additional phase follow-ups might
be appropriate in patients at high risk for pseudophakic
CME.30,31 Research on the risks for and prevention of pseu-
dophakic CME is still required to minimize postoperative
complications of uneventful cataract surgery, especially
concerning patients with diabetes.
To conclude, the findings in this study suggests consid-
ering serum HbA1c when assessing a patient’s risks for pseu-
dophakic CME. Clinical characteristics such as patient age,
type of diabetes and insulin dependency, and posterior
segment manifestations of disease should also be considered.WHAT WAS KNOWN
 Diabetes is a risk factor for pseudophakic CME.
 The extent of diabetic posterior segment manifestations
adds to the risk for pseudophakic CME.
WHAT THIS PAPER ADDS
 A diabetic patient’s risk for pseudophakic CME was asso-
ciated with poor glycemic control, which was determined by
the high serum HbA1c level.
 It is necessary to identify, effectively treat, and follow-up with
patients who have diabetes and are at a greater risk for
pseudophakic CME.
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